Allopurinol is one of the most commonly prescribed medications for gout and high uric acid levels, and most people tolerate it well over years of use. The long-term side effects that matter fall into two broad categories: rare but serious reactions, particularly severe skin and hypersensitivity reactions that carry real danger, and subtler concerns involving the liver, kidneys, blood cells, and eyes that accumulate relevance the longer someone stays on the drug. What makes allopurinol unusual among chronic medications is that your genetic background can dramatically change your risk profile, and certain drug combinations can turn a safe medication into a dangerous one.
Severe Skin Reactions Are the Most Feared Long-Term Risk
The side effect that keeps doctors watchful is a severe cutaneous adverse reaction, which includes Stevens-Johnson syndrome and toxic epidermal necrolysis. These are life-threatening conditions where the skin essentially blisters and peels off, sometimes involving the mouth, eyes, and other mucosal surfaces. While rare in absolute terms, allopurinol is one of the most commonly implicated drugs worldwide for these reactions. A study comparing outcomes found that people who developed SJS or TEN from allopurinol had a mortality rate of about 18%, compared with roughly 8% for the same reactions triggered by other drugs.1PubMed. Unique Clinical Characteristics and Prognosis of Allopurinol-Induced Severe Cutaneous Adverse Reactions
These reactions most often appear within the first few weeks to months of starting treatment. Case reports describe onset as early as ten days after the first dose.2PubMed Central. Allopurinol-Induced Stevens–Johnson Syndrome (SJS) That timing matters because it means the risk is highest during the initial months, which is also when many people consider allopurinol a “new” medication and may not connect a developing rash with it. Anyone who develops a widespread rash, especially with mouth sores, eye irritation, or fever after starting allopurinol, should seek emergency medical attention. The longer-term implication is that people who tolerate the first few months without incident carry a much lower risk going forward, though vigilance for skin changes should never fully stop.
The HLA-B*5801 Gene and Who Is Most Vulnerable
A landmark study in Han Chinese patients found that a specific genetic marker, HLA-B*5801, was present in every single one of 51 patients who developed severe skin reactions to allopurinol, but in only about 15% of people who tolerated the drug without problems.3Proceedings of the National Academy of Sciences. HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol This gene variant is recognized as the single most important risk factor for allopurinol-induced severe skin reactions.4PubMed. Efficacy of the HLA-B(∗)58:01 Screening Test in Preventing Allopurinol-Induced Severe Cutaneous Adverse Reactions in Patients with Chronic Renal Insufficiency-A Prospective Study
How useful the test is depends on your ancestry. A systematic review and meta-analysis found that screening for HLA-B*5801 has high sensitivity in Korean, Thai, Sardinian Italian, and Han Chinese populations (pooled sensitivity around 97%), meaning the test catches nearly all at-risk individuals. In European and Japanese populations, sensitivity drops to roughly 50-60%, which means the test misses about half of the people who would go on to have a severe reaction.5International Journal of Rheumatic Diseases. Diagnostic utility of HLA‐B*5801 screening in severe allopurinol hypersensitivity syndrome: an updated systematic review and meta‐analysis Current guidelines generally recommend testing before starting allopurinol in people of Southeast Asian, Korean, or African American descent, where the allele is more common. For people of European ancestry, testing is recommended in some guidelines but not universally mandated.
Kidney Disease Changes the Risk Calculus
Allopurinol is converted in the body to oxypurinol, which does the actual work of lowering uric acid. Oxypurinol is cleared mainly through the kidneys, and in people with reduced kidney function, oxypurinol accumulates to higher-than-normal levels.6PubMed. Clinical pharmacokinetics and pharmacodynamics of allopurinol and oxypurinol That buildup is believed to be one reason why hypersensitivity reactions, including severe skin reactions, occur more frequently in people with kidney impairment.7Seminars in Dialysis. Allopurinol Dosing in Renal Impairment: Walking the Tightrope Between Adequate Urate Lowering and Adverse Events
This creates a genuine clinical dilemma. Dose-reduction guidelines have existed for decades, recommending lower allopurinol doses in people with poor kidney function. But those reduced doses often fail to bring uric acid levels down to the target range, leaving gout undertreated. At the same time, research has shown that severe reactions can occur even at low doses, so cutting the dose does not eliminate the risk entirely. A population-based study in older adults with chronic kidney disease found that starting allopurinol at doses above 100 mg per day roughly doubled the risk of a severe skin reaction compared to starting at 100 mg or less.8PubMed. Initiation Dose of Allopurinol and the Risk of Severe Cutaneous Reactions in Older Adults With CKD: A Population-Based Cohort Study The practical takeaway is that starting low and increasing slowly is the safest approach, especially if your kidneys are not working at full capacity.
Does Allopurinol Protect or Harm the Kidneys Over Time?
For years, there was hope that lowering uric acid with allopurinol might slow the progression of chronic kidney disease. The evidence on this is mixed and somewhat disappointing. A large, well-designed trial published in the New England Journal of Medicine found that allopurinol did not slow kidney function decline compared to placebo in patients with chronic kidney disease at high risk of progression.9PubMed. Effects of Allopurinol on the Progression of Chronic Kidney Disease
However, a smaller, longer-running study with a median follow-up of seven years told a more encouraging story: patients randomized to allopurinol had fewer kidney events than the control group over the long term.10PubMed. Allopurinol and progression of CKD and cardiovascular events: long-term follow-up of a randomized clinical trial And in a specific inherited kidney condition called familial juvenile hyperuricaemic nephropathy, early treatment with allopurinol did help preserve kidney function over more than a decade, with siblings who started treatment early maintaining stable function while untreated family members deteriorated.11QJM: An International Journal of Medicine. Early treatment with allopurinol in familial juvenile hyerpuricaemic nephropathy (FJHN) ameliorates the long‐term progression of renal disease The bottom line is that allopurinol does not appear to harm the kidneys directly, but its ability to protect them depends heavily on the specific situation. For garden-variety chronic kidney disease, the kidney-protective case has not held up to rigorous testing.
Cardiovascular Outcomes
Whether allopurinol helps or hurts the heart has been a genuine source of confusion, partly because of one large trial that muddied the waters. The CARES trial compared allopurinol to febuxostat (an alternative uric acid-lowering drug) in gout patients with cardiovascular disease and found that cardiovascular events occurred at similar rates in both groups, roughly 10-11%.12PubMed. Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout Because that trial used allopurinol as the comparator rather than placebo, it could not tell us whether allopurinol itself was safe in absolute terms.
A later trial, ALL-HEART, directly tested whether allopurinol could reduce cardiovascular events in patients with existing heart disease. It found no benefit at all: rates of heart attack, stroke, and cardiovascular death were virtually identical between the allopurinol group and the usual-care group.13PubMed Central. Allopurinol and cardiovascular outcomes in patients with ischaemic heart disease: the ALL-HEART RCT and economic evaluation Importantly, all-cause mortality was also equivalent between groups, which is reassuring: allopurinol did not help the heart, but it did not appear to damage it either.
A European trial comparing febuxostat and allopurinol head to head (the FAST trial) found that febuxostat was noninferior to allopurinol for cardiovascular safety, and overall death rates were similar between the two drugs.14The Lancet. Cardiovascular safety of febuxostat or allopurinol in patients with gout (FAST) A meta-analysis pooling data across trials found no significant difference in cardiovascular death or all-cause mortality between the two medications.15PubMed Central. Cardiovascular safety of febuxostat compared to allopurinol for the treatment of gout: A systematic and meta‐analysis That said, adverse-event reporting data have flagged some cardiovascular signals for allopurinol, including peripheral swelling, atrial fibrillation, and heart failure as commonly reported events.16PubMed Central. Cardiovascular Safety Evaluation of Febuxostat and Allopurinol: Findings from the FDA Adverse Event Reporting System Adverse-event databases pick up signals that clinical trials might miss, but they also overcount because people report events that may not be caused by the drug. On balance, allopurinol appears cardiovascularly neutral for most people.
Liver Effects
Allopurinol can occasionally injure the liver, and when it does, the damage tends to appear as part of a broader hypersensitivity reaction rather than as an isolated liver problem. A detailed study of confirmed allopurinol hepatotoxicity cases found that the median time from starting the drug to onset of liver injury was about 52 days. Hypersensitivity features were extremely common: roughly 91% of patients had a rash and about 45% had fever or elevated eosinophils (a type of white blood cell that rises during allergic-type reactions). All patients were symptomatic and required hospitalization.17PubMed Central. Allopurinol hepatotoxicity is associated with HLA Class I Alleles
A systematic review of randomized controlled trials found that mild to moderate bumps in liver function tests occur with both allopurinol and febuxostat, and most studies show no significant difference between the two drugs in liver safety.18Therapeutics and Clinical Risk Management. Hepatic Safety of Febuxostat and Allopurinol for Gout Patients: A Systematic Review of Randomized Controlled Trial So while your doctor may check liver enzymes periodically when you are on allopurinol, the liver abnormalities in clinical trials are typically mild and often resolve on their own. Severe liver injury is rare and seems to be genetically driven, similar to the severe skin reactions.
Blood Cell Effects
Allopurinol can, in rare cases, suppress the bone marrow’s ability to produce blood cells. The most serious form of this is aplastic anemia, where the marrow essentially stops making enough red cells, white cells, and platelets. Case reports describe fatal outcomes from allopurinol-induced aplastic anemia, though the event is uncommon enough that many prescribers never encounter it in their careers.19PubMed Central. Allopurinol: Sorrow to the marrow
Where blood cell effects become a much more practical concern is when allopurinol is combined with certain other drugs, particularly azathioprine or its close relative 6-mercaptopurine. Both are immunosuppressants used in organ transplant patients and in some autoimmune conditions. Azathioprine is normally broken down in part by the same enzyme that allopurinol blocks (xanthine oxidase). When allopurinol shuts down that breakdown pathway, active drug metabolites build up to toxic levels and can cause severe, life-threatening drops in white blood cells and platelets.20PubMed Central. Pancytopenia caused by allopurinol and azathioprine interaction in a heart transplant patient: a case report If you are on azathioprine or 6-mercaptopurine and need uric acid lowering, your doctor should either avoid allopurinol entirely or dramatically reduce the dose of the immunosuppressant with very close monitoring.
Eye Health and Cataract Suspicions
One long-running concern about allopurinol involves the eyes. Early reports from the National Registry of Drug-Induced Ocular Side Effects accumulated 30 cases of suspected lens changes in people taking allopurinol. The pattern typically started with changes in the front and back of the lens capsule, progressing over time to denser cataracts.21PubMed. Cataracts associated with allopurinol therapy The authors were careful to note that these cases did not prove causation, but raised enough suspicion that periodic eye exams are sometimes recommended for long-term users.
The cataract question has never been definitively settled with a large controlled trial. Because cataracts are extremely common in older adults (the same population that takes allopurinol), teasing apart drug effect from normal aging is difficult. Still, if you have been on allopurinol for several years and notice vision changes, it is worth mentioning the medication to your eye doctor.
Pregnancy and Reproductive Safety
Allopurinol is not commonly prescribed to women of childbearing age, but when it is, reproductive safety becomes a serious question. A review of 53 allopurinol-exposed pregnancies reported in the literature found that the overall rate of major birth defects (about 4%) and spontaneous miscarriages fell within the normal range for the general population. However, two cases showed a strikingly similar pattern of severe malformations, raising concern about a potential, if rare, teratogenic effect.22PubMed Central. Allopurinol Use during Pregnancy – Outcome of 31 Prospectively Ascertained Cases and a Phenotype Possibly Indicative for Teratogenicity
A comprehensive review of both animal and human data concluded that the association between allopurinol and birth defects appears weak and is limited to those two case reports with uncertain causation, but the total amount of data is still too small to be confident either way.23PubMed. The teratogenicity of allopurinol: A comprehensive review of animal and human studies The practical advice is to avoid allopurinol during the first trimester if possible and to discuss alternatives with your doctor if you are planning a pregnancy.
Effects on the Brain
Some people on allopurinol report headaches, drowsiness, or a general foggy feeling, but these complaints are hard to quantify and often improve over time. The more interesting long-term question is whether allopurinol affects cognitive decline or dementia risk. An updated meta-analysis found that long-term allopurinol use was not associated with an increased risk of dementia. When one particularly influential study was removed from the analysis, the remaining data actually pointed toward a modest protective effect.24Pharmacy Practice. Possible Effect of Allopurinol and Risk of Dementia: An Updated Meta-Analysis
Separately, allopurinol has been studied as an add-on treatment in bipolar disorder. A randomized, placebo-controlled trial found that adding allopurinol to standard treatment for acute mania significantly improved symptoms, and the probability of remission after four weeks was dramatically higher in the allopurinol group.25PubMed. In a double-blind, randomized and placebo-controlled trial, adjuvant allopurinol improved symptoms of mania in in-patients suffering from bipolar disorder This is not a side effect of allopurinol per se, but it illustrates that the drug has neurobiological activity beyond simply lowering uric acid, which is relevant when thinking about why some people feel “different” on it.
Metabolic Effects and Blood Sugar
Given that gout patients often have metabolic syndrome, diabetes, or prediabetes, whether allopurinol worsens or improves blood sugar control is a practical question. A large Veterans Affairs cohort study following gout patients for an average of about eight years found no significant difference in the rate of new type 2 diabetes between allopurinol users and non-users.26PubMed Central. Allopurinol use and type 2 diabetes incidence among patients with gout: a VA retrospective cohort study
Interestingly, in people with high uric acid but no gout symptoms, a smaller study found that allopurinol treatment improved fasting blood glucose, insulin levels, and markers of insulin resistance, along with reducing a marker of systemic inflammation. The number of people with impaired fasting glucose dropped substantially after three months on allopurinol.27PubMed. Lowering Uric Acid With Allopurinol Improves Insulin Resistance and Systemic Inflammation in Asymptomatic Hyperuricemia These findings suggest that lowering uric acid may improve metabolic parameters in the short term, but the long-term diabetes risk does not appear to change meaningfully. For people worried about allopurinol making their blood sugar worse, the evidence is reassuring.
Managing Skin Reactions if You Need the Drug
For people who develop a mild rash on allopurinol but have few alternative uric acid-lowering options, slow oral desensitization is sometimes an option. A study of patients who had experienced skin eruptions from allopurinol found that a gradual desensitization protocol was effective and safe over the long term, particularly in gout patients who could not use other medications. Itchy skin reactions sometimes recurred during or after the process, but most could be managed by temporarily pausing the drug and adjusting the dose.28PubMed. Efficacy and safety of desensitization to allopurinol following cutaneous reactions Desensitization is only appropriate for mild cutaneous reactions. Anyone who has had SJS, TEN, or drug reaction with eosinophilia and systemic symptoms should never be re-exposed to allopurinol under any circumstances.
Early Gout Flares Are Not a Side Effect of Long-Term Use
One thing that often gets confused with a “side effect” is the gout flare that commonly happens when people first start allopurinol or when their dose is increased. As uric acid levels drop, crystals that have been sitting in joints can shift and trigger an inflammatory response. This is a temporary phenomenon of the early treatment phase, not a long-term side effect of the drug itself. With continued treatment, these flares taper off as the body’s uric acid stores are depleted. Doctors typically prescribe anti-inflammatory prophylaxis during the first several months to manage this, and starting at a low dose with gradual increases helps minimize flare frequency.
The distinction matters because many people abandon allopurinol during this early flare period, thinking the drug is making their gout worse. In reality, it is a sign that the drug is working, and pushing through (with appropriate flare management) leads to fewer attacks over the long haul.
How Oxypurinol Accumulation Shapes Long-Term Risk
Much of allopurinol’s long-term risk profile traces back to its main metabolite, oxypurinol. Allopurinol itself disappears from the bloodstream quickly, but roughly 90% of each dose is converted to oxypurinol, which has a half-life of about 23 hours in people with normal kidneys.6PubMed. Clinical pharmacokinetics and pharmacodynamics of allopurinol and oxypurinol Oxypurinol accumulates with daily dosing, and its levels climb progressively during the early weeks of treatment. Up to 80% of each allopurinol dose is recovered in the urine within 24 hours, mostly as oxypurinol.29Clinical Pharmacokinetics. Clinical Pharmacokinetics of Allopurinol
This means that anything reducing kidney clearance, whether aging, dehydration, chronic kidney disease, or certain other medications, can push oxypurinol levels higher and raise the risk of hypersensitivity reactions. It also explains why the severe skin reactions are thought to involve the immune system reacting to oxypurinol itself rather than to allopurinol. For long-term users, periodic checks of kidney function are not just routine box-ticking; they directly inform whether your current dose is likely to be safe or whether oxypurinol may be building up to concerning levels.